About Us

CoLucid Pharmaceuticals is an innovative biotechnology company focusing on therapies for central nervous system (CNS) disorders. CoLucid is leading a paradigm shift in migraine therapy with the clinical development of a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA). These compounds are designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapy. In addition, the company is developing a rich pipeline of novel chemical entities (NCEs) for therapy of sleep/wake disorders, chronic pain, Alzheimer’s disease and psychiatric disorders.

---

Product Pipeline

Our lead product candidate COL-144 is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapy. COL-144 selectively targets 5HT1F receptors expressed in the trigeminal nerve pathway. We completed a Phase II clinical trial in 2007 examining the efficacy of COL-144 in the acute treatment of migraine after intravenous administration. Based on the exciting results of that trial, we are advancing clinical development of COL-144 toward Phase III as an oral treatment for migraine.

In addition, our pipeline includes a conjugated stigmine platform that has generated a series of preclinical candidates for the treatment of  sleep/wake disorders, chronic pain, Alzheimer’s disease and anxiety/depression disorders. COL-204, the lead compound in the conjugated stigmine program, is targeted for clinical development for wake promotion.

Neurally Acting Anti-Migraine Agents | Conjugated Stigmine Platform | Pipeline Overview